Clinical trials: Homologous Recombination Deficient Solid Tumors

Homologous Recombination Deficient Solid Tumors

Niraparib and Dostarlimab in HRD Solid Tumors

• Unknown status
• Age: Up to 100 years
• Phase 2

This is an open-label, single-arm, Phase 2 study which will evaluate the efficacy and safety of niraparib and dostarlimab (TSR-042) combination in patients with metastatic, recurrent, or unresectable solid tumor with a…

Trial name

DIDO (NCT04983745)

Testing

Combination drug

Where

United States

Volunteers

30 people

Sponsor

West Cancer Center